{
    "clinical_study": {
        "@rank": "156549", 
        "arm_group": {
            "arm_group_label": "Docetaxel + Stereotactic Radiation", 
            "arm_group_type": "Experimental", 
            "description": "Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety of a chemotherapy drug called\n      docetaxel and focused radiation therapy (SBRT) and see what effects (good and bad) it has on\n      recurrent head and neck cancer that is not surgically removable."
        }, 
        "brief_title": "Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent or second primary squamous cell head and neck cancer\n\n          -  Defined area of recurrence on imaging\n\n          -  Previous head and neck radiation (RT) to >/= 50 Gy\n\n          -  Performance status score 0-1\n\n          -  Time interval from previous RT >/= 9 months\n\n          -  Volume of disease appropriate for protocol treatment\n\n          -  Minimum estimated survival of >/= 3 months\n\n          -  Age >/= 18\n\n          -  Adequate labs\n\n        Exclusion Criteria:\n\n          -  Primary tumors of the salivary gland\n\n          -  Original pathology report and radiation therapy records not available\n\n          -  Prior spinal cord dose > 45 Gy\n\n          -  Surgery or chemotherapy within 4 weeks\n\n          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free\n             for a minimum of 3 years; noninvasive cancers are permitted"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110992", 
            "org_study_id": "UCCI-HN-13-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Docetaxel + Stereotactic Radiation", 
                "description": "Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Taxotere", 
                    "NDC 0075-8001-20"
                ]
            }, 
            {
                "arm_group_label": "Docetaxel + Stereotactic Radiation", 
                "description": "SBRT will be given over 5 fractions separated by > 48 hours.  Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.", 
                "intervention_name": "Stereotactic Radiation", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "SBRT", 
                    "Stereotactic Body Radiation", 
                    "Radiation Therapy"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "kastla@ucmail.uc.edu", 
                "last_name": "UC Cancer Institute Clinical Trials Office", 
                "phone": "513-584-7698"
            }, 
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45267-0502"
                }, 
                "name": "University of Cincinnati Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Michelle Mierzwa, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck", 
        "overall_contact": {
            "email": "kastla@ucmail.uc.edu", 
            "last_name": "UC Cancer Institute Clinical Trials Office", 
            "phone": "513-584-7698"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Michelle Mierzwa, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Acute dose limiting toxicity is defined as grade 4 or 5 toxicity measured by the Common Toxicity Criteria for Adverse Effects (CTCAE) v 4.0, including carotid arterial rupture", 
            "measure": "Number of acute dose limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110992"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Michelle Mierzwa", 
            "investigator_title": "Radiation Oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from enrollment until local failure or death (whichever comes first)", 
                "measure": "Locoregional control", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time from enrollment until disease progression anywhere in the body or death (whichever comes first)", 
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Time from enrollment to death from any cause", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Occuring > 3 months after treatment completion, including grade 4 and 5 toxicities measured by CTCAE v 4.0 involving skin, mucosa, larynx, pharynx, spinal cord, cranial nerves, and incidence of caroid blowout.", 
                "measure": "Number of late effect dose limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}